March 2007 Oncology News International

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Ibrutinib/Nivolumab Shows Clinical Activity in R/R CNS Lymphoma

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/ nivolumab combination regimen, 3 were in remission beyond 2 years.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/ nivolumab combination regimen, 3 were in remission beyond 2 years.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

Loncastuximab Tesirine Combo Demonstrates Early Efficacy in R/R DLBCL

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System

The safety profile of loncastuximab tesirine plus glofitamab was consistent with the known profiles of the individual agents.

Nathalie Soler, MD;Kelly Paz Amador, MD;Alexandra Perez, MD;Camila Solis, MD;Alexander Reyes, MD;Jorge Garcia, MD;Maria Paula Gonzalez Zambrano, MD;Edgar Fabián Manrique Hernández, MD, MSc, PhD (c)

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.

Related Content

Sheng Chow;Meredith Shamamian;Susan Laura Jao;Andreina Giron;Jessica Lin;Fardeen Bhimani;Eleni Kohilakis;Caroline Oska;Jana Fox;Sheldon Feldman;Maureen McEvoy

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD

May 12th 2025

Ibrutinib/Nivolumab Shows Clinical Activity in R/R CNS Lymphoma

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/ nivolumab combination regimen, 3 were in remission beyond 2 years.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

May 5th 2025

Loncastuximab Tesirine Combo Demonstrates Early Efficacy in R/R DLBCL

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.